Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CALA: Updated Results from Phase 1 Study of Telaglenastat (CB-839) to be Presented at 2019 ASCO Genitourinary Cancer Symposium
link
Scientists show that drugs targeting tumor metabolism will not stop natural killer cells
MedicalXpress
happy new year ADXS board, bought today my first position in ADXS,
glta,
Sik
the consensus revenue estimate was $4,53 million, not $11 million for Q3
earnings history
CALA expanded its existing clinical collaboration with Bristol-Myers Squibb, evaluating CB-839 in combination with Opdivo®
Initial data from the ongoing trial of CB-839 in combination with Opdivo® in patients with melanoma, renal cell carcinoma and non-small cell lung cancer will be presented Saturday, November 11th, 2017, at the Society for Immunotherapy of Cancer
more on news link:
news link
some thoughts on this?
ty, sik
Glutamine addiction in kidney cancer suppresses oxidative stress and can be exploited for real-time imaging
...Upon glutaminase inhibition with CB-839 or BPTES, the RCC cell lines SN12PM-6-1 (SN12) and 786-O exhibited decreased survival and pronounced apoptosis associated with a decreased GSH/GSSG ratio, augmented nuclear factor erythroid related factor 2 (NRF2), and increased 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), a marker of DNA damage. SN12 tumor xenografts showed decreased growth when treated with CB-839...
Link: American Association for Cancer Research
Experimental Calithera compound cripples key lung cancer mutations
...The researchers found that a mutated gene called KEAP1 teams up with another abnormal gene, KRAS, to cause lung cancer cells to grow aggressively. In so doing, they expel one type of glutamate and break down another to make energy. When the scientists tested CB-839 in mouse models of lung adenocarcinomas that had both mutations, the drug stopped the tumor growth....
Link: fiercebiotech
someone knows when the new Ford Focus will be presented?
Wells Fargo & Co increase PT to 20$
source on twitter
Next week presentation on Keystone symposia:
THURSDAY, MARCH 9
Ethan Emberley, Calithera Biosciences, USA
Short Talk: CB-839, a Selective Glutaminase Inhibitor, has Anti-Tumor Activity in Renal Cell Carcinoma and Synergizes with Everolimus and Cabozantinib
program
2 new cb-839 studies:
CB-839 + Azacitidine for Treatment of Myelodysplastic Syndrome (MDS)
cinical trials.gov
Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC
clinical trials.gov
Compositions and Methods for Inhibiting Arginase Activity
Publication Number:20160375044
Publication Date: 29.12.2016
link patenscope
COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY
Pub. No.: WO/2016/210106
Publication Date: 29.12.2016
link patentscope
HETEROCYCLIC INHIBITORS OF GLUTAMINASE
Publication Number: 10201607685S
Publication Date: 29.11.2016
link patentscope
Publication Number:20160376297
Publication Date: 29.12.2016
Phosphorous Derivatives as Kinase Inhibitors
link patentscope
Publication Number: 20160368917
Publication Date: 22.12.2016
Bicyclic Heteroaryl Compounds
Abstract:
(EN) This invention relates to compounds of the general formula:
link patenscope
CALA; BMY: Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma (ccRCC).
CALA + 25% premarket
news link
Alexandria, Nov. 16 - Ariad Pharmaceuticals Obtains Patent for Crystalline Forms of 3-(Imidazo[1,2-B] Pyridazin-3-Ylethynyl)-4-Methyl-N-{4-[(4-Methylpiperazin-1-Yl) Methyl]-3-(Trifluoromethyl)Phenyl}Ben..
global ip news
(WO2016183278) HETEROARYL COMPOUNDS FOR KINASE INHIBITION
Publication Date: 17.11.2016
Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.
patentscope
Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers
Application Number: 15044382
Application Date: 16.02.2016
Publication Number: 20160244469
Publication Date: 25.08.2016
patentscope
This week Complete Rolling Submission of New Drug Application of Brigatinib with priority review?
...FDA informs the applicant of a Priority Review designation within 60 days of the receipt of the original BLA, NDA, or efficacy supplement...
link
New trial at ClinicalTrials.gov:
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Sponsor:
Case Comprehensive Cancer Center
link
they didnt report q2 numbers yesterday, when is the release?
Jabbour talked about Pona on investors day, but still nice to read
Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
bloodjournal
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
RESULTS
Propensity score matching identified 41 patients in each cohort. With propensity score matching, the 3-year EFS rates for patients treated with HCVAD plus ponatinib and HCVAD plus dasatinib were 69% and 46%, respectively (P =.04), and the 3-year OS rates were 83% and 56%, respectively (P =.03). IPTW analysis using prematching cohorts demonstrated that patients treated with HCVAD plus ponatinib had significantly higher rates of minimal residual disease negativity by flow cytometry on day 21, complete cytogenetic response at complete response, major molecular response at complete response and at 3 months, and complete molecular response at 3 months. IPTW confirmed that treatment with HCVAD plus ponatinib was associated with longer EFS (P =.003) and OS (P =.001) compared with treatment with HCVAD plus dasatinib.
CONCLUSIONS
The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL. Cancer 2016. © 2016 American Cancer Society.
link
We can assume that Ariad is also charging patients for free in the
Expanded Access Study of Brigatinib?
Sry have no idea about this compassionate use programm.
Seems to be common?
The announcement of Key Strategic Objectives for 2017 will come Jan. or Feb. next Year.
2016:
ARIAD Reports 2015 Financial Results, Provides 2016 Product Revenue Guidance and Outlines Company Progress
2015:
ARIAD Announces Key Strategic Objectives for 2015 Expected to Lead Company to Profitability in Three Years
Think youre right, FDA will approve brigatinib not as fast as Ponatinib.
Ponatinib was one of the fastest approvals ever.See link
CDER Drug and Biologic Accelerated and Restricted Distribution Approvals
The week after next we´ll complete the rolling submission of NDA (60 days after NDA), and then up to 6 month for Briga approval, -if they get granted the priority review
This was the timeline from Ponatinib approval:
07/30/2012 ARIAD Announces Submission of New Drug Application..
09/27/2012 ARIAD Completes Rolling Submission of New Drug Application..
10/24/2012 ARIAD Announces U.S. FDA Acceptance of NDA..
12/14/2012 ARIAD Announces Accelerated Approval by FDA..
glta,
Sik
Houston,Texas,USA September15-18,2016 18th Annual John Goldman Conf.
Long-term efficacy and safety of ponatinib in heavily pretreated leukemia patients: 4-year results from the pivotal phase 2 PACE trial
-Jorge Cortes (Houston)
Impact of early responses on 3-year outcomes in heavily pretreated CP-CML patients: landmark analyses in the pivotal ponatinib PACE trial
-Martin C.Müller (Mannheim)
preliminary program
ESMO,Copenhagen,Denmark October 07-11, Annual Congress 2016
-ALTA-1L (ALK in lung cancer trial of BrigAtinib in 1st Line): A randomized, phase 3 trial of brigatinib versus crizotinib in TKI–naive, advanced ALK–positive NSCLC
(Camidge, Kerstein...)
-Brigatinib in patients with ALK–positive NSCLC in a phase 1/2 trial
(Camidge, Kerstein, Haluska...)
preliminary program
i think 2017 updates will come with brigatinib approval
Thanks to Denner,Panayiotopoulos and the whole Ariad team for these great q2 earnings. The company moves to the right direction, sharholder value come true and isnt a empty phrase anymore
ARIA:
ARIAD Pharmaceuticals (NASDAQ:ARIA): Q2 GAAP EPS of $0.56 beats by $0.67.Revenue of $68.13M (+133.0% Y/Y) beats by $7.49M.
Press Release
Some speculations why Clackson sold so many shares last and this year?
Now he sold monthly since march.
2015 he sold 165.257 stocks ($ 1.523.042)
this year he sold 157.079 stocks ($ 1.108.678)
so he sold 322.336 stocks 2015+2016, he still have 248.208 stocks.
see Insider trades on marketbeat.com
Why do you think he do that?
He´s out of ariad soon and have to sold? (i dont think so)
He´s investing rather in gold & silver?
...?
kind regards,
Sik
Thats strange. 2M+ Volume, and price is up 1%? Someone can explain that?
Wow, look at the short interests.
A decrease by 22% (!)
Short Interest - Prior 2,022,900
Short Interest - atm 1,572,700
Days To Cover 6,6
Promising Secondary Endpoints for Ponatinib in CML Despite Early EPIC Trial Termination
“Ponatinib is not an option for first-line therapy at this time,” said Dr Lipton. “But successful completion of the OPTIC studies with a demonstration of reduced toxicity and sustained efficacy may open up the possibility of revisiting another study in newly diagnosed patients.”
cancertherapyadvisor.com
Q1 2016 Financial Highlights (Ballard Power)
(all comparisons are to Q1 2015 unless otherwise noted)
--Material Handling revenue was $4.1 million, an increase of 59% due to increased fuel cell stack shipments to Plug Power
Ballard Reports First Quarter 2016 Results
Waiting for breakout, with nice squeeze.
Cala 28,07% of float short, 26,2 days to cover.
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating: Buy (Score: 3.00)
Consensus Price Target: $12.00
U.S. Patent and Trademark Office has received Ariad Pharmaceuticals's patent application for crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-benzamide and its mono hydrochloride salt.
Fri 06 Nov 2015
Global IP News
Australia registers leukaemia drug in benefit scheme
BioSpectrum